Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2Bi-armed T cells
- Development stage
- Unknown
- Lead developer
- Barbara Ann Karmanos Cancer Institute
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
HER2Bi-armed T cells is an investigational autologous cell-based immunotherapy being evaluated for the treatment of HER2-positive digestive system neoplasms. The therapy consists of expanded autologous T cells that are coated ex vivo with bispecific antibodies (HER2Bi) targeting both CD3 on the T cells and human epidermal growth factor receptor 2 (HER2) on tumor cells. This 'arming' process allows the T cells to specifically target and lyse HER2-expressing cancer cells without requiring genetic modification. In clinical protocols, these armed T cells are typically administered intravenously in combination with low-dose subcutaneous interleukin-2 (IL-2) to enhance the survival, proliferation, and cytotoxic activity of the infused cells. The therapy is being investigated by Yi Miao for a range of gastrointestinal cancers, including esophageal, gastric, pancreatic, liver, gallbladder, and bowel cancers.
- Other names
- HER2Bi-Armed Activated T CellsHER-2Bi-Armed Activated T CellsHER 2Bi-Armed Activated T CellsHER2Bi-Armed T CellsHER-2Bi-Armed T CellsHER 2Bi-Armed T Cellsanti-CD3 x anti-HER2 bispecific antibody-armed T cellsanti-CD-3 x anti-HER2 bispecific antibody-armed T cellsanti-CD 3 x anti-HER2 bispecific antibody-armed T cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on HER2Bi-armed T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2Bi-armed T cells.